PD-L1 is a potential biomarker to predict the response to pembrolizumab monotherapy in 1L metastatic patients with NSCLC harboring PD-L1 tumor proportion score (TPS) ≥ 1% [8]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.